Disease Landscape and Forecast Insights

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to…

No disease-modifying agents have been developed to treat myelodysplastic syndromes (MDS). All pharmacological approaches to treat the disease—growth factor stimulants (e.g., erythropoietin-…

Immune thrombocytopenia purpura (ITP) is an autoimmune form of acquired thrombocytopenia that leads to a decrease in platelet production and an increased risk of bleeding. Current therapies for ITP…

Immunoglobulin A nephropathy (IgAN), also known as Berger’s disease, is a rare autoimmune disease affecting the kidneys. It is characterized by predominant IgA protein deposition and impairment…

Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Symptoms include severe anemia, weakness, fatigue, and splenomegaly…

Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin in red blood cells that distorts them into a sickle shape. This sickling leads to several…

The treatment landscape for COVID-19 continues to evolve rapidly. Despite the availability of vaccines in the markets under study, ongoing research focuses on decreasing viral loads and improving…

The treatment of ovarian cancer has historically been dominated by chemotherapy, but angiogenesis and PARP inhibitors are optimizing treatment options. The regulatory approvals of AstraZeneca /…

Diabetic macular edema (DME) is caused by diabetes and is characterized by leaking fluid from abnormal blood vessels in the eye; this fluid can lead to swelling of the macula and visual impairment…

According to Clarivate Epidemiology, there are approximately 4 million prevalent cases of Alzheimer’s disease (AD) and nearly 2.5 million prevalent cases of mild cognitive impairment (MCI) due to…

The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six new agents have been approved by the FDA (four of them since the start of 2021),…

Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and PCSK9…